Cargando…
Should Cell Culture Platforms Move towards EV Therapy Requirements?
Autor principal: | Aiastui, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309209/ https://www.ncbi.nlm.nih.gov/pubmed/25674086 http://dx.doi.org/10.3389/fimmu.2015.00008 |
Ejemplares similares
-
Comparison of EV-free fraction, EVs, and total secretome of amniotic mesenchymal stromal cells for their immunomodulatory potential: a translational perspective
por: Papait, Andrea, et al.
Publicado: (2022) -
Clinical Grade Regulatory CD4(+) T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies
por: Duggleby, Richard, et al.
Publicado: (2018) -
The role of mesenchymal stem cell-derived EVs in diabetic wound healing
por: Jiang, Min, et al.
Publicado: (2023) -
Overview of Digital Twin Platforms for EV Applications
por: Ibrahim, Mahmoud, et al.
Publicado: (2023) -
Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment
por: Van Morckhoven, David, et al.
Publicado: (2023)